HUMANISED ANTIBODIES AND USES THEREOF

Abstract: A humanised antibody capable of binding to the MUC1 mucin antigen comprises a light chain and a heavy chain. The variable region of the light chain (VL) comprising an amino acid sequence which is substantially homologous with the sequence of Fig.1A and the variable region of the heavy chain (VH) comprising an amino acid sequence which is substantially homologous with the sequence of Fig. 1B. The amino acid residue at position 46 on VL is backmutated to arginine, and the amino acid residue at position 47 on VH is backmutated to leucine. The humanised antibody has use in the diagnosis and/or treatment of cancer.

Description: HUMANISED ANTIBODIES AND USES THEREOF INTRODUCTION The invention relates to a humanised version of the murine C595 antibody, and to uses of the humanised antibody in the diagnosis, staging and treatment of cancers. The MUC1 mucin is expressed by secretory epithelia. Its abberant glycosylation in tumours allows it to be exploited as a marker for antibody targeted diagnosis and therapy. The C595 murine monoclonal antibody targets the epitope Arg-Pro-Ala-Pro on the MUC1 protein core. It has been used both in-vitro and in-vivo in the diagnosis of breast and bladder cancer. A phase 1 clinical trial of the antibody as a radioimmunotherapeutic agent in bladder cancer by intravesical administration has recently been initiated. Its potential use as an intravenous diagnostic has been limited by its murine origin. It is an object of the invention to overcome this problem. STATEMENTS OF INVENTION Accordingly, the invention provides a humanised antibody capable of binding to the MUC1 mucin antigen comprising a light chain and a heavy chain, the variable region of the light chain (VL) comprising an amino acid sequence which is substantially homologous with the sequence of Fig.lA, the variable region of the heavy chain (VH) comprising an amino acid sequence which is substantially homologous with the sequence of Fig.lB wherein the amino acid residue at position 46 on VL is backmutated to arginine, and wherein the amino acid residue at position 47 on VH is backmutated to leucine. The VL domain is joined to the human immunoglobulin Kappa constant domain to form the complete light chain. Similarly, the V H domain is joined to the human immunoglobulin gamma-1 constant domains to form the complete heavy chain. In this specification the term "substantially homologous" should be understood as meaning that the degree of homology is sufficient to allow binding to the MUC1 mucin antigen when any of the various backmutation combinations of the invention are included. Thus, stated another way, the antibodies according to the invention comprise a light chain and a heavy chain, the VL domain of the light chain comprising a framework region (FR) derived from the Bence Jones protein REI and complementarity-determining regions (CDR) derived from the murine C595 antibody, the FR including at least one backmutation at position 46 to arginine, the VH domain of the heavy chain comprising a FR derived from myeloma protein HIL and CDR derived from murine C595 antibody, the FR including at least one backmutation at position 47 to leucine. Typically, the VL domain will have at least a 60%, preferably at least 70%, more preferably at least 80%, more preferably at least 90%, and most preferably at least 95% homology with the amino acid sequence of Fig.lA Similarly, the V H domain will typically have at least a 60%, preferably at least 70%, more preferably at least 80%, more preferably at least 90%, and most preferably at least 95% homology with the amino acid sequence of Fig.lB. Preferably, the VL domain will include further backmutations to improve binding affinity. In one embodiment of the invention the amino acid residue at position 4 of the VL domain is backmutated to leucine. Preferably, the amino acid residues at positions 4 and 1 of the VL domain are backmutated to leucine and glutamine respectively. Ideally, the amino acid residues at positions 4, 1 and 47 on the VL domain are backmutated to leucine, glutamine and tryptophan respectively. The combination of these three backmutations with the backmutation on residue 46 of the VL domain has the effect of increasing the affinity of the humanised antibody for the antigen seven-fold. Suitably, the amino acid residues at positions 4, 1 , 47 and 3 on the VL domain are backmutated to leucine, glutamine, tryptophan and valine respectively. Typically, the amino acid residues at positions 4, 1 , 47, 3, 40 and 70 on the VL domain may be backmutated to leucine, glutamine, tryptophan, valine, serine and serine respectively. In another embodiment of the invention, the amino acid residues at positions 4 and 47 on the V L domain are backmutated to leucine and tryptophan. In a further embodiment of the invention the amino acid residue at position 47 on the VL domain is backmutated to tryptophan. In a still further embodiment of the invention, the amino acid residues at positions 1 , 3 and 4 on the VL domain are backmutated to glutamine, valine and leucine. The possible permutations for back mutations to the V L domain according to the invention is summarised in Table 2A. Preferably, the VH domain will include further backmutations. Thus, for example, the backmutation of the amino acid residue at position 42 on the VH domain to aspartic acid has been found to increase the binding affinity of the antibody two-fold. Furthermore, the backmutation of the amino acid residue at position 16 on the VH domain to glycine has been demonstrated to reduce the non-specific binding of the antibody to other unrelated antigens. The possible backmutation permutations of the VH domain according to the invention are summarised in Table 2B. Most preferably, the humanised antibody comprises the backmutation indicated as BMLr in Table 2A and the backmutation indicated as BMHq in Table 2B. The VL domain according to the invention typically comprises a framework region (FR) and complementarity determining regions (CDR), wherein the FR region is derived from the Bence Jones protein REI, and wherein the CDR is obtained from the C595 antibody. The VH domain according to the invention typically comprises a framework region (FR) and complementarity determining regions (CDR), wherein the FR region is derived from the myeloma protein HIL, and wherein the CDR is obtained from the C595 antibody. In a preferred embodiment of the invention, the humanised antibody according to the invention is conjugated to a radioactive isotope. Ideally, the radioactive isotope is selected from the group of Technetium-99m, Rhenium- 188, Copper-67 and lndium-111. The invention also relates to the use of a humanised antibody according to the invention in the diagnosis and/or treatment of cancer, in the intravesical diagnosis and/or therapy of bladder tumour and/or bladder cancer, in the intravenous diagnosis, staging and/or therapy of metastatic bladder cancer, and in the intravenous diagnosis and/or therapy of localised and/or metastatic cancers expressing the MUC1 mucin antigen, especially bladder, breast and ovarian cancers. The invention also relates to a variable light chain domain (VL) for a humanised antibody according to the invention comprising an amino acid sequence which has a sufficient degree of homology with the sequence of Fig.lA to allow binding to the MUC1 mucin antigen when one of the backmutation combinations given in Table 2A is included. The invention also relates to a variable heavy chain domain (VH) for a humanised antibody according to the invention and comprising an amino acid sequence which has a sufficient degree of homology with the sequence of Fig.l B to allow binding to the MUC1 mucin antigen one of the backmutation combinations given in Table 2B is included. The invention also relates to the use of the VL domain and/or the VH domain of the invention in the formation of a humanised antibody and/or an antibody binding fragment (e.g. single chain FV antibody, diabody, and other multivalent derivatives) which is capable of binding to the MUC1 mucin antigen. The invention also seeks to provide a method for the treatment or diagnosis of cancer, comprising administering an effective amount of a humanised antibody according to the invention to a patient. The invention also provides a humanised antibody according to the invention for use in the manufacture of a medicament for the treatment or diagnosis of cancer. DETAILED DESCRIPTION OF THE INVENTION Preparation of human framework regions for CDR grafting: The framework regions (FRs) from the Bence-Jones protein REI [VL, Protein databank [PDB] access code: 1REI, Kabat subgroup (Kabat et al., 1991): human kappa I] and the myeloma protein HIL (VH, PDB access code: 8FAB, Kabat subgroup: human heavy III) were used as acceptor FRs for the CDRs from C595 in CDR grafting. A number of amino acid residues in these FRs were substituted by the consensus residue at those positions within the corresponding subgroup because of their relatively low occurrence in the subgroups and are therefore likely to have arisen from idiosyncratic mutations (table 1). These substitutions ensure that the human FRs represents human immunoglobulin sequences as a whole, rather than an individual sequence containing unnecessary mutations (which may only be useful for that particular antibody). All substituted residues are already present in the original murine C595 sequence and therefore such substitutions should not be detrimental to antigen binding. Tyr-71(V L ) was not substituted because it is positioned in the Vernier zone (Foote and Winter, 1992) of C595 VL and may have important interactions with the CDRs. Table 1. Residues in the FRs of (a) 1rei and (b) 8fab which deviate from the consensus sequence within their Kabat subgroups. (A) 1rei (VL) - human subgroup kappa I Residue Occurrence in Kabat Substitution by consensus subgroup (%) (first letter = original residue number = Kabat residue number last letter = consensus substitution) Thr-39 3 T39K Tyr-71 3 No - Vernier zone residue Phe-73 26 - lle-83 21 - Leu-104 24 - Thr-107 5 T107K (B) 8fab (VH) - human subgroup heavy III Residue Occurrence in Substitution by consensus (first letter = original residue Kabat subgroup ( /o) number = Kabat residue number last letter = consensus substitution) PCA*-1 12 PCA1E* Lys-3 2 K3Q Gln-6 6 Q6E Ala-7 2 A7S Val-11 25 Arg-16 28 lle-23 2 I23A Ala-49 30 Arg-76 2 R76N Met-80 3 M80L Thr-84 10 Val-107 2 V107T PCA = pyrollidone carboxylic acid CDR grafting: The finalised FRs were joined to CDRs from C595 to form the sequence BLC595a. The complete amino acid sequence of the BLC595a variable region is shown in figure 1. The DNA sequence for BLC595a was then deduced according to common codon usage for immunoglobulins (Kabat et al, 1991). To this DNA sequence, a cassette containing the recognition sequence for the restriction enzyme Hindlll [(AAG:CTT) (other suitable restriction enzyme recognition sequences may also be used for subcloning into expression vectors)], the Kozak initiation sequence (Kozak, 1987) and an immunoglobulin signal peptide sequence from the antibody sharing the highest sequence homology with the corresponding humanised V and VH domains (i.e. BLC595 V L and V H ) published in the Kabat database (Kabat et al., 1991) were added upstream. Also, a splice donor site (Bendig and Jones, 1996; optional depending on the expression vectors used) and the recognition sequence for the restriction enzyme BamHI [(GGA:CTT), or other appropriate restriction enzyme recognition sequence] were added downstream to this sequence. This whole sequence (i.e. Hindlll-Kozak-signal-BLC595 V L /Vπ-splice donor- BamHI; to be referred to as "the encoding sequence") for each of VL and VH was then analysed for the presence of internal splice donor and restriction sites (e.g. BamHI/HindHi) with the Genetics Computer Group (GCG) Wisconsin Package v.9.0. The complete DNA encoding sequences for BI_C595a VL and VH are shown in figure 2. The encoding sequences were synthesised de novo by the polymerase chain reaction (PCR). Eight overlapping oligonucleotide primers (each of around 80-nucleotide in length; figure 2) were synthesised to cover each of the VL and VH encoding sequences for BLC595a in a series of PCRs (Bendig and Jones, 1997; figure 3). The PCR products representing full length V and V H were cloned and their sequences confirmed to yield the CDR-grafted sequence BLC595a. PCR for BLC595a construction (Referring to Fig.3) 1) Reactions 1 and 2: 5μL Geneamp 10x PCR buffer with 15mM MgCI 2 (Perkin- Elmer) 1 μl_ 10mM dNTP Mix (Sigma) 12.5pmol each of PL/H1 , 2, 3, 4 (reaction 1 - V L Λ H ) or PL H5, 6, 7, 8 (reaction 2 V Λ/ H ) 2.5units AmpliTaq DNA polymerase (Perkin Elmer) + sufficient sterilised, deionised water to 50μl_ Conditions: 1) 94°C - 5 minutes (hot start) 2) 94°C - 2 minutes ) x 8 cycles 72°C - 5 minutes ) 3) 72°C - 10 minutes ) Reactions 3, 4 and 6 5μL Geneamp 10x PCR buffer with 15mM MgCI 2 (Perkin- Elmer) 1μL 10mM dNTP Mix (Sigma) 5μL PCR product from reaction 1 (reaction 3, V Λ/H), reaction 2 (reaction 4, VLΛ H) or reaction 5 (reaction 6 - VL/VH) 40pmol each PNLHA and PNLB2 (reaction 3, V L ) PNLHA and PNHB2 (reaction 3, V H ) PNLC2 and PNLD (reaction 4, V L ) PNHC2 and PNHD (reaction 4, V H ) PNLHE and PNLF (reaction 6, V L ) PNLHE and PNHF (reaction 6, V H ) 2.5units AmpliTaq DNA polymerase (Perkin Elmer) + sufficient sterilised, deionised water to 50μL Conditions: 1) 94°C - 5 minutes (hot start) 2) 94°C - 1.5 minutes ) 64°C - 1.5 minutes ) x 20 cycles 72°C - 2.5 minutes ) 3) 72°C - 10 minutes 3) Reaction 5: 5μL Geneamp 10x PCR buffer with 15mM MgCI 2 (Perkin- Elmer) 1 μl_ 10mM dNTP Mix (Sigma) 5μL each PCR products from reactions 3 and 4 (VLΛ H) 2.5units AmpliTaq DNA polymerase (Perkin Elmer) + sufficient sterilised, deionised water to 50μL Conditions: 1) 94°C - 5 minutes (hot start) 2) 94°C - 2 minutes ) x 8 cycles 72°C - 5 minutes ) 3) 72°C - 10 minutes Introduction of backmutations: Backmutations are defined as the substitution of the amino acid residue at a position in the chosen human framework with the residue at the same position in the mouse antibody C595. These were introduced in an attempt to optimise the antigen binding ability of BLC595 after CDR grafting. Mutations were introduced by the method of overlap extension PCR (Higuchi et al., 1988). All mutants were cloned and sequenced prior to antibody expression. A number of backmutants of VL and VH were made that incorporated one or more such amino acid backmutations. The positions for backmutations were determined initially on the common framework positions known to affect CDR conformations [namely, the Vernier zone (Foote and Winter, 1992), VL/VH interface (Chothia et al., 1985), VL N-terminal residues (Padlan, 1994) and putative O- and N-glycosylation syites (Bendig and Jones, 1997)]. These were exhausted before other backmutations were explored. In the case of BLC595, it was mainly the other backmutations, which were not obvious from previous publications, that led to a high level of restoration to specific MUC1 binding. Mutations in all the backmutants (represented by BMLx for VL mutants and BMHx for V H mutants) are shown in table 2 below. Table 2. Mutations incorporated into the human frameworks. The first letter of each backmutation indicates the original amino acid residue in the human framework. The number indicates the amino acid position (Kabat numbering system; Kabat et al, 1991). The last letter indicates the new amino acid residue after backmutation. (A) BLC595 V L backmutants Final BLC595 sequence and antibody expression. The final BLC595 variable region consists of the backmutants BMLr and BMHq. The complete amino acid sequences are shown in figure 4. The encoding sequences for BMLr and BMHq were excised from the cloning vector by appropriate restriction digests and were subcloned into expression vectors containing the human constant regions kappa and gamma-1 respectively for whole IgG expression (for example, pKN10 - light chain; pG1D16/20 - heavy chain - from Medical Research Council Technology). These BLC595 expression vectors (for example, 10μg each of pKN10- BLC595 V L and pG1D16/20 - BLC595 V H ) were then co-transfected into 7x10 6 COS-7 cells by electroporation at 1900V, 25μF. Cells were then transferred to 8mLs of pre-warmed medium (Dulbecco modified eagle medium supplemented with 10% (v/v) ultra low lgG-foetal bovine serum, 580 μg/ml L- glutamine and 50 Units/ml penicillin / 50 μg/ml streptomycin). Antibodies were harvested in the medium 48-72 hours post transfection. Purified BLC595 was obtained by standard Sepharose-protein A affinity chromatography. Methods for Radiolabelling of Antibodies We envisage the use of 99m Tc (or other gamma-emitting isotopes) as a diagnostic radionuclide and 188 Re (or other gamma- and beta-emitting isotopes) as a diagnostic/ therapeutic radionuclide for BLC595. Labelling of antibodies with these radioisotopes are available in the literature and references are given below: 1) Technetium-99m: Pimm MV, Gribben SJ (1993) Radiolabelling antibodies for imaging and targeting. In: Tumour Immunobiology; A Practical Approach (Gallagher, Rees & Reynolds, eds) pp 209-223. Oxford University Press, (also for rhenium-188) Mather SJ & Ellison D (1990) Reduction mediated technetium-99m labelling of monoclonal antibodies. J. Nucl. Med Z . 692-697. 2) Rhenium-188: Griffiths GL, Goldenberg DM, Diril H & Hansen HJ (1994) Technetium- 99m, Rhenium-186 and Rhenium-188 direct-labeled antibodies. Cancer 73: 761-768. Potential Usage of BLC595-based Radiopharmaceuticals Superficial Bladder Cancer: Intravesical Administration The antibody can be utilised via the intravesical administration of BLC595 conjugated to radioactive isotopes to detect the presence of MUC1 mucin positive tumour cells within the confines of the bladder. Radionuclides include both 67 Cu and 99m Tc for diagnostic purposes. Allied to the use of 99m Tc is the isotope 188 Re, which has similar chemical characteristics to 99 Tc but with a appropriate beta emission for cellular cytotoxicity and as such can be exploited in a therapeutic context. In a similar manner 67 Cu can be used in both a diagnostic and therapeutic scenario (it has both gamma and beta energy emission) although routine use of 67 Cu would be limited because it is not readily available widely. Bladder Cancer: Invasive and Metastatic Disease The same arguments apply for the use of BLC595 by systemic administration in the diagnosis and the treatment of metastatic bladder cancer. In human bladder cancer, we are not aware of the use of similar approaches using other radiolabelled anti-MUC1 mucin monoclonal antibodies. The humanised nature of BLC595 allow it to be administered repeatedly in multiple dosing regimens, whilst keeping the likelihood of human anti-mouse antibody (HAMA) response to a minimum. As a diagnostic and disease staging tool, preliminary data has shown that systemic use of the parent antibody C595 coupled to 111 ln, 67 Cu, 99m Tc and 188 Re would have the potential to be as useful as, if not better than, magnetic resonance imaging in instances where metastatic disease expresses MUC1. In the same way we would see therapeutic doses of radiolabelled antibody being utilised to treat patients of their disease. Ovarian Cancer Pre-clinical and clinical evaluation of the use of BLC595-based radioimmunoconjugates in the bladder cancer model should lead to their application in other diseases where MUC1 tumour expression is well characterised. This includes breast and ovarian carcinomas. In an ovarian study, we would use our reagents in diagnosis by their administration into the peritoneum. Because of the involvement of the hosts immune system in this cavity, the humanised antibody conjugate would offer the greatest chance of evading the HAMA response. Multiple administration for potential therapeutic effect could therefore be envisaged. Metastatic ovarian cancers may also be detected and treated in the same manner as metastatic bladder cancer using BLC595 conjugated to the aforesaid radionuclides. Metastatic Breast Cancer We could also see BLC595 finding a suitable role in the diagnosis and possible management of breast cancer. This again would involve systemic administration of the radioimmunoconjugate. Current Phase l/l I Trials Our use of 67 Cu labelled C595 in a diagnostic context has been published. We now have approval from the Cancer Research Campaign (CRC) to begin a Phase I clinical trial in human bladder cancer using 67 Cu -labelled C595 administered intravesically. Phase II trails using similar protocols should commence upon the completion of this study. This should ascertain the clinical utility of our radioimmunoconjugate (proof of principle) and should lead to similar trials being set up using 88 Re labelled C595, a more widely available radionuclide and therefore more commercially viable. Similar studies with radiolabelled BLC595 would follow after appropriate preclinical evaluation. The way forward into the systemic usage of this antibody would then be forged, so that experimentation on disseminated disease can progress. The use of appropriate higher does of this radioimmunoconjugate would see the use of this reagent in a potential therapeutic context. The invention is not limited to the embodiments hereinbefore described which may be varied in construction and detail without departing from the spirit of the invention. References Bendig MM, Jones ST (1996) Rodent to human antibodies by CDR grafting. IN: McCafferty J, Hoogenboom, HR, Chiswell DJ (eds) Antibody engineering - a practical approach. NEW YORK: Oxford University Press. Chothia C, Novotny J, Bruccoleri R, Karplus M (1985) Domain association in immunoglobulin molecules - the packing of variable domains. J Mol Biol 186:651-663. Foote J, Winter G (1992) Antibody framework residues affecting the conformation of the h pervariable loops. J Mol Biol 224:487-499 Higuchi R, Krummel B, Saiki RK (1988) A general method of in vitro preparation and specific mutagenesis of DNA fragments: Study of protein and DNA interactions. Nucleic Acids Res 16:7351-7367 Kabat EA, Wut TT, Perry HM, Gottesman KS, Foeller C (1991) Sequences of proteins of immunological interest. 5 th edition. BETHESDA: US Department of Health and Human Services. Kozak M (1987) At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells. J Mol Biol 196:947-950 Padlan EA (1994) Anatomy of the antibody molecule. Mol Immunol 31 (3): 169-217.

Claims: CLAIMS 1. A humanised antibody capable of binding to a MUC1 mucin antigen comprising a light chain and a heavy chain, the variable region of the light chain (V ) comprising an amino acid sequence which is substantially homologous with the sequence of Fig.lA, the variable region of the heavy chain (VH) comprising an amino acid sequence which is substantially homologous with the sequence of Fig.lB, wherein the amino acid residue at position 46 on V L is backmutated to arginine, and wherein the amino acid residue at position 47 on VH is backmutated to leucine. 2. A humanised antibody as claimed in claim 1 in which the amino acid residue at position 4 of V is backmutated to leucine. 3. A humanised antibody as claimed in claim 2 in which the amino acid residue at position 1 of V is backmutated to glutamine. 4. A humanised antibody as claimed in claim 3 in which the amino acid residue at position 47 on VL is backmutated to tryptophan. 5. A humanised antibody as claimed in claim 4 in which the amino acid residue at position 3 on VL is backmutated to valine. 6. A humanised antibody as claimed in claim 5 in which the amino acid residues at positions 40 and 70 on VL are backmutated to serine. 7. A humanised antibody as claimed in claim 1 in which the amino acid residue at position 47 on VL is backmutated to tryptoptian. 8. A humanised antibody as claimed in claim 2 in which the amino acid residue at position 3 on VL is backmutated to valine. 9. A humanised antibody as claimed in claim 3 in which the amino acid residue at position 47 on V is backmutated to tryptophan. 10. A humanised antibody as claimed in any preceding claim in which the amino acid residue at position 42 on VH is backmutated to aspartic acid. 11. A humanised antibody as claimed in claim 10 in which the amino acid residue at position 16 on VH is backmutated to glycine. 12. A humanised antibody as claimed in claim 10 in which the amino acid residue at position 44 on V H is backmutated to arginine. 13. A humanised antibody as claimed in claim 10 in which the amino acid residue at position 11 on VH is backmutated to leucine. 14. A humanised antibody as claimed in claim 10 in which the amino acid residue at position 19 on V H is backmutated to lysine. 15. A humanised antibody as claimed in any of claims 1 to 9 in which the amino acid residues at positions 11 , 16 and 19 on VH are backmutated to leucine, glycine and lysine respectively. 16. A humanised antibody as claimed in any of claims 1 to 9 in which the amino acid residues at positions 40, 82a and 108 on VH are backmutated to threonine, serine and threonine respectively. 17. A humanised antibody as claimed in any of claims 1 to 9 in which the amino acid residue at position 74 on VH is backmutated to alanine. 18. A humanised antibody as claimed in any of claims 1 to 9 in which the amino acid residue at position 89 on VH is backmutated to methionine. 19. A humanised antibody as claimed in any of claims 1 to 9 in which the amino acid residues at positions 108 and 109 on VH are backmutated to threonine and leucine respectively. 20. A humanised antibody as claimed in any of claims 1 to 9 in which the amino acid residue at positions 83 and 84 on VH are backmutated to lysine and serine respectively. 21. A humanised antibody as claimed in any preceding claim in which the VL domain comprises a framework region (FR) and complementarity determining regions (CDR), wherein the FR region comprises the Bence Jones protein REI, and wherein the CDR are obtained from C595 antibody. 22. A humanised antibody as claimed in any preceding claim in which the VH domain comprises a framework region (FR) and complementarity determining regions (CDR), wherein the FR region comprises the myeloma protein HIL, and wherein the CDR are obtained from C595 antibody. 23. A humanised antibody as claimed in any preceding claim conjugated to a radioactive isotope. 24. A humanised antibody as claimed in claim 23 in which the radioactive isotope is selected from the group of Technetium-99m, Rhenium-188, Copper-67 and lndium-111. 25. Use of a humanised antibody as claimed in any preceding claim in the diagnosis and/or treatment of cancer. 26. • Use of a humanised antibody as claimed in any preceding claim in the intravesical diagnosis and/or therapy of bladder tumour and/or bladder cancer. 27. Use of a humanised antibody as claimed in any preceding claim in the intravenous diagnosis, staging and/or therapy of metastatic bladder cancer. 28. Use of a humanised antibody as claimed in any preceding claim in the intravenous diagnosis and/or therapy of localised and/or metastatic cancers expressing the MUC1 mucin antigen, especially bladder, breast and ovarian cancers. 29. A variable light chain domain (V ) for a humanised antibody according to any of claim 1 to 22 comprising an amino acid sequence which has a sufficient degree of homology with the sequence of Fig.lA to allow binding to the MUC1 mucin antigen when one of the backmutation combinations given in Table 2A is included. 30. A variable heavy chain domain (V H ) for a humanised antibody according to any of claims 1 to 22 and comprising an amino acid sequence which has a sufficient degree of homology with the sequence of Fig.lB to allow binding to the MUC1 mucin antigen when one of the backmutation combinations given in Table 2B is included. 31. Use of the VL domain of claim 29 and/or the VH domain of claim 30 in the formation of a humanised antibody and/or an antibody binding fragment which is capable of binding to the MUC1 mucin antigen. 32. A method for the treatment or diagnosis of cancer, comprising administering an effective amount of a humanised antibody according to any of claims 1 to 24 to a patient. 33. A humanised antibody according to any of claims 1 to 24 for use in the manufacture of a medicament for the treatment or diagnosis of cancer. 34. A nucleic acid sequence which codes for any of the humanised antibodies of claims 1 to 22 or either of the V domain of claim 29 or V domain of claim 30.

Inventors: LAUGHTON CHARLES ANTHONY, LO BENNY KWAN CHING, PRICE MICHAEL RAWLINGS DI, LAUGHTON, CHARLES, ANTHONY, LO, BENNY, KWAN, CHING, PRICE, MICHAEL, RAWLINGS DI
Applicants: CRC TECHNOLOGY LTD, LAUGHTON CHARLES ANTHONY, LO BENNY KWAN CHING, PRICE FRANCES MARGARET LF, UNIV NOTTINGHAM, CRC TECHNOLOGY LIMITED, LAUGHTON, CHARLES, ANTHONY, LO, BENNY, KWAN, CHING, PRICE, FRANCES, MARGARET LF, THE UNIVERSITY OF NOTTINGHAM
Application year: 2001
Main classification: C07K16
IPC codes: A61K51, C07K16